Dexamethasone Acetate — Drug Intelligence | 35 EU Trials

Filter these 35 trials by condition, phase, country and more.

Open in Search →

35 Registered trials

14 Recruiting

15 Completed trials

22 Sponsors

22 Countries

Phase III

Phase II

Phase I/II

Phase III: 16 Phase II: 9 Phase I/II: 6 Phase I: 1 Phase I (FiH): 3

Oversight events:

3 serious breaches 50 temporary halts 2 urgent safety measures 4 unexpected events 1 corrective measure across 13 trials

View oversight register →

Indications tested

Metastasis 1 Retinitis pigmentosa 1 Amyloidosis 1 End stage renal disease 1 Hormone receptor positive breast cancer 1 Primary mediastinal large B-cell lymphoma 1 Diffuse large B-cell lymphoma 1 Osteosarcoma 1 Breast cancer 1 High-grade B-cell lymphoma 1 Neuroblastoma 1 B-cell lymphoma refractory 1

Sponsors using this IMP

Merck Sharp & Dohme LLC 8 Centre Hospitalier Universitaire De Nantes 2 Emn Trial Office S.r.l. Impresa Sociale 2 European Myeloma Network B.V. 2 F. Hoffmann-La Roche AG 2 Genmab A/S 2 Intergroupe Francophone Du Myelome 2 Oslo University Hospital HF 2 Universitaetsklinikum Muenster AöR 2 AbbVie Deutschland GmbH & Co. KG 1 Assistance Publique Hopitaux De Paris 1 BeOne Medicines AG 1

All trials — page 2

35 total

A Study of combination of Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) compared to VELCADE, Lenalidomide, and … Ended

2023-506125-10-00 Phase III 11 countries Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.
AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia Ended

2023-509856-32-00 Phase III 5 countries Universitaetsklinikum Schleswig-Holstein
A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma Ended

2023-504802-12-00 Phase I (FiH) 9 countries Genmab A/S
Multicenter, Dose-Escalation and Expansion Study of Combination Therapy with Venetoclax, Daratumumab and Dexamethasone (with and without Bor… Ended

2023-506110-43-00 Phase I/II 3 countries AbbVie Deutschland GmbH & Co. KG
B-NHL 2013 - Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and… Ended

2023-505509-18-00 Phase III 7 countries Universitaetsklinikum Muenster AöR
Extended Criteria Treatment for Liver Metastases With Heavy Tumour Burden Halted

2024-512397-95-00 Phase II 1 country Oslo University Hospital HF
A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101) Ended

2023-508422-95-00 Phase I/II 1 country Synthorx Inc.
EFFICACY AND SAFETY TRIAL OF EPCORITAMAB WITH OR WITHOUT LENALIDOMIDE AS FIRST LINE THERAPY FOR SUBJECTS WITH DIFFUSE LARGE B-CELL LYMPHOMA. Ended

2023-504832-16-00 Phase II 8 countries Genmab A/S
Tisagenlecleucel in adult patients with aggressive B-cell non-Hodgkin lymphoma Ended

2023-508343-48-00 Phase III 7 countries Novartis Pharma AG
KRd consolidation in myeloma patients with a positive PET-CT after standard first line treatment. A phase II study Ended

2024-511714-20-00 Phase II 2 countries Oslo University Hospital HF
IFM 2020-01 (Isamyp) Efficacity assessment of isatuximab plus pomalidomide and dexamethasone in patients with AL amyloidosis who didn't reac… Ended

2024-513887-25-00 Phase II 1 country Intergroupe Francophone Du Myelome

Showing 25–35 of 35 trials

← All drugs A–Z